Cel-Sci Corporation - CVM

Cel-Sci Corporation (CVM)
http://www.cel-sci.com/
Coverage: June 13, 2009 - December 13, 2009
Featured: June 13, 2009

The WHO (I'm not kidding- World Health Organization) has officially declared the Swine Flu as a world wide pandemic. This past week, the WHO raised the Swine Flu to "Phase 6", it's highest level for global risk. The Phase 6 alert does not mean the severity is increasing- it means the spread is more global. The Phase 6 ranking opens the door to accelerated production and research on a number of possible therapies and vaccines.

One company getting major recognition for a possible therapy is AMEX listed Cel-Sci (AMEX: CVM), a stock I have been following on and off for many years. Last week, CVM announced its L.E.A.P.S (Ligand Epitope Antigen Presentation System) technology, could represent an immune based therapy for swine flu, and had shown promise. At the Naval Medical Research Center in Silver Spring, MD, L.E.A.P.S has demonstrated an ability to enhance the body's natural protection against many different kinds of diseases. The Navy is focused on using the therapy to treat Malaria. This past week, Cel-Sci announced it was developing an immune based treatment for the Swine Flu, and the stock went absolutely ballistic.

Cel-Sci traded 32 million shares in one day last week, the highest volume in its more than 20 years of being a publicly traded company under the ticker CVM. CVM also surged from about $.25 to $.80 in one day. Pretty crazy.

Latest Newsletter Editions

spacer
Sat, Jan 16, 2010 @ 09:01 am
The Biotech Buzz Rerun I looked for some recent small stock biotech winners. Check out the action in ECTE of late. $1.30 to $2.20 this month on increasing volume as the stock climbs the charts. There's a lot of action in these small biotechs right now. Do you believe in reincarnation? In the stock market...
Wed, Jan 13, 2010 @ 11:01 am
The China/Biotech Buzz It's been a very strong week for my China ideas, with several of the top choices delivering strong news and making new all time highs this week. Review and comments on the hot China ideas below. Biotechs are buzzing right now, and a great number of small cap/biotech stocks are...
Wed, Dec 2, 2009 @ 08:12 am
Coming Attractions You might recall an edition I published about a month ago suggesting it was time to step back, take a look at every idea, and set some cash aside to get past tax selling season and into December. The time has come. I suspect December will be a good month in the markets. Small stocks...
Mon, Nov 9, 2009 @ 02:11 pm
You Asked For It; You'll Get It As expected, lots of you read about my Interclick (NASDAQ: ICLK) idea over the weekend, and sent me the same comment: Why didn't you tell us about this one back in May when it was still under $1 on the Bulletin Board? Point taken- after all, isn't that the goal of investing...
Sat, Oct 10, 2009 @ 04:10 pm
A Couple More Updates: Cel-Sci (AMEX: CVM) and CalAmp (NASDAQ: CAMP) There's lots more action to cover from this past week, so let's get to two more of the actively traded ideas I have shared of late. Cel-Sci (NYSE AMEX: CVM): The Squawking and Finger Pointing Was Inevitable CVM, one of the hottest...

Click Here For More Newsletters on CVM

spacer

Latest Blog Entries

spacer

Quote Data

spacer
Last Trade: 0.54 Bid: 0.5400
Last Size: 1,461 Ask: 0.5400
Trade Time: 4:00pm Bid x Ask Size: 100x4500
Change: down arrow -0.0200 (-3.57%) Day's Range: 0.53 - 0.57
Prev Close: 0.5600 52wk Range: 0.48 - 1.23
Open: 0.5500 P/E (ttm): N/A
Volume: 293,957 EPS (ttm): -0.43
spacer [Chart]

Business Summary

spacer
CEL-SCI Corporation, a biotechnology company, engages in research and development of drugs and vaccines for the treatment of cancer and infectious diseases. The company’s primary product Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines under phase II clinical trail for the treatment of cancer. It also develops CEL-1000 peptide product with its Ligand Epitope Antigen Presentation System technology which is under preclinical stage for the protection/treatment of animals against herpes, malaria, viral encephalitis, and cancer. The company markets its products to cancer centers, physicians, and clinics involved in immunotherapy. CEL-SCI was founded in 1983 and is based in Vienna, Virginia.

Disclosure

spacer
TGR Group LLC, an affiliate of MarketByte LLC, has been paid a fee of 100,000 newly issued restricted shares by Cel-Sci Corporation, for coverage of the Company.

Recent News Headlines

spacer
NEW STORY CEL-SCI Reports August Patient Enrollment for Its Phase 3 Head and Neck Cancer Trial
Tue, 01 Sep 2015 21:04:06 GMT
[at noodls] - CEL-SCI REPORTS AUGUST PATIENT ENROLLMENT FOR ITS PHASE 3 HEAD AND NECK CANCER TRIAL Vienna, VA, September 1, 2015 -- CEL-SCI Corporation (NYSE MKT: CVM) ('CEL SCI' or the 'Company') today announced that ...
4:31 pm CEL-SCI Corp announces that it enrolled 19 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine in August, totaling 540
Tue, 01 Sep 2015 20:31:00 GMT
CEL-SCI Reports August Patient Enrollment for Its Phase 3 Head and Neck Cancer Trial
Tue, 01 Sep 2015 20:30:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that in the month of August it has enrolled 19 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* in patients with advanced primary squamous cell carcinoma of the oral cavity/soft palate, a type of head and neck cancer.
"CEL-SCI Corporation's (NYSE MKT: CVM) Unique Phase III Cancer Immunotherapy Trial Advances" is the Topic of Flaherty Financial Newsletter #50 While its Stock Remains Bob F's Best Buy
Tue, 01 Sep 2015 12:00:00 GMT
[Accesswire] - WEST HARRISON, NY / ACCESSWIRE / September 1, 2015 / The continuing progress of CEL-SCI Corporation (NYSE MKT: CVM), arguably the most undervalued Phase III biotech company, is profiled in the August 27th ...
CEL SCI CORP Financials
Wed, 19 Aug 2015 17:04:08 GMT
10-Q for CEL-SCI Corp.
Mon, 10 Aug 2015 00:13:03 GMT
NEW STORY CEL-SCI Corporation Reports Third Quarter Fiscal Year 2015 Financial Results
Sat, 08 Aug 2015 11:33:16 GMT
[at noodls] - CEL-SCI CORPORATION REPORTS THIRD QUARTER FISCAL YEAR 2015 FINANCIAL RESULTS Vienna, VA, August 7, 2015 -- CEL-SCI Corporation (NYSE MKT: CVM) today reported financial results for the quarter ended June ...
CEL SCI CORP Files SEC form 10-Q, Quarterly Report
Fri, 07 Aug 2015 22:26:34 GMT
Cel-Sci reports 3Q loss
Fri, 07 Aug 2015 20:36:56 GMT
Cel-Sci reports 3Q loss
Fri, 07 Aug 2015 20:36:56 GMT
CEL-SCI Corporation Reports Third Quarter Fiscal Year 2015 Financial Results
Fri, 07 Aug 2015 20:30:00 GMT
[Business Wire] - CEL-SCI Corporation today reported financial results for the quarter ended June 30, 2015.
NEW STORY CEL-SCI Reports Record Monthly Patient Enrollment in July for Its Phase 3 Head and Neck Cancer Trial
Mon, 03 Aug 2015 13:24:15 GMT
[at noodls] - CEL-SCI REPORTS RECORD MONTHLY PATIENT ENROLLMENT IN JULY FOR ITS PHASE 3 HEAD AND NECK CANCER TRIAL 33 patients enrolled in July brings total to over 500 Vienna, VA, August 3, 2015 -- CEL-SCI Corporation ...
NEW STORY CEL-SCI Expands Its Phase I Study For Treatment of Anal Warts in HIV/HPV Co-Infected Patients with Addition of 2nd Site at University of California San Francisco
Mon, 03 Aug 2015 13:24:15 GMT
[at noodls] - CEL-SCI EXPANDS ITS PHASE I STUDY FOR TREATMENT OF ANAL WARTS IN HIV/HPV CO-INFECTED PATIENTS WITH ADDITION OF 2ND SITE AT UNIVERSITY OF CALIFORNIA SAN FRANCISCO Renowned Key Opinion Leader, Dr. Joel Palefsky, ...
CEL-SCI Reports Record Monthly Patient Enrollment in July for Its Phase 3 Head and Neck Cancer Trial
Mon, 03 Aug 2015 13:00:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that in July it has enrolled 33 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* in patients with advanced primary head and neck cancer.
HIV/HPV Guru Comes on Board to Battle Cancer, Driving CEL-SCI's Multi-billion Dollar Market Opportunity
Tue, 28 Jul 2015 13:00:00 GMT
[Accesswire] - NEW YORK, NY / ACCESSWIRE / July 28, 2015 / Advancing promising clinical research past government funded trials is big milestone for biotechs and often comes with a corresponding move in the company's ...
CEL-SCI Expands Its Phase I Study for Treatment of Anal Warts in HIV/HPV Co-Infected Patients with Addition of 2nd Site at University of California San Francisco
Mon, 20 Jul 2015 12:30:00 GMT
[Business Wire] - CEL-SCI Corporation today announced it has added a second clinical site for its Phase I clinical trial evaluating peri-anal wart immunotherapy in HIV/HPV co-infected men and women with its investigational cancer immunotherapy Multikine* .
CEL SCI CORP Files SEC form 8-K, Entry into a Material Definitive Agreement
Wed, 01 Jul 2015 21:11:52 GMT
CEL-SCI Reports June Patient Enrollment in Its Phase 3 Head and Neck Cancer Trial
Wed, 01 Jul 2015 13:20:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that in June it has enrolled 25 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* in just diagnosed, not yet treated patients with head and neck cancer.
CEL SCI CORP Files SEC form 8-K, Change in Directors or Principal Officers
Tue, 30 Jun 2015 17:12:44 GMT
CEL-SCI Corporation (NYSE MKT: CVM), Arguably the Most Undervalued Phase III Biotech, is Updated in Flaherty Special Situation Newsletter as Bob F's Best Buy
Mon, 29 Jun 2015 12:15:00 GMT
[Accesswire] - WEST HARRISON, NY / ACCESSWIRE / June 29, 2015 / CEL-SCI Corporation, (NYSE MKT: CVM), arguably the most undervalued Phase III biotech company, is featured in the June 25 issue of Flaherty Special Situation ...